The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 30, 2024
Filed:
Oct. 06, 2021
The Broad Institute, Inc., Cambridge, MA (US);
The Brigham & Women's Hospital, Inc., Boston, MA (US);
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Instituto Carlos Slim DE LA Salud, A.c., Mexico City, MX;
Anna Greka, Boston, MA (US);
Moran Dvela-Levitt, Cambridge, MA (US);
Maria Alimova, Cambridge, MA (US);
Eric Lander, Cambridge, MA (US);
Todd R Golub, Cambridge, MA (US);
Florence Wagner, Cambridge, MA (US);
Brian Chamberlain, Cambridge, MA (US);
Valeria Padovano, Cambridge, MA (US);
Joseph Growney, Cambridge, MA (US);
The Broad Institute, Inc., Boston, MA (US);
The Brigham and Women's Hospital, Boston, MA (US);
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Instituto Carlos Slim De La Salud, A.C., Mexico City, MX;
Abstract
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.